Neurofilament phosphoforms: surrogate markers for axonal injury, degeneration and loss.
about
Tau elevations in the brain extracellular space correlate with reduced amyloid-β levels and predict adverse clinical outcomes after severe traumatic brain injuryBiomarkers of therapeutic response in multiple sclerosis: current statusNew aspects of the pathogenesis of canine distemper leukoencephalitisSacs knockout mice present pathophysiological defects underlying autosomal recessive spastic ataxia of Charlevoix-SaguenayCharcot-Marie-Tooth causing HSPB1 mutations increase Cdk5-mediated phosphorylation of neurofilamentsPlasma neurofilament heavy chain levels correlate to markers of late stage disease progression and treatment response in SOD1(G93A) mice that model ALSElevation of 20-carbon long chain bases due to a mutation in serine palmitoyltransferase small subunit b results in neurodegenerationCaspase-mediated cleavage of actin and tubulin is a common feature and sensitive marker of axonal degeneration in neural development and injuryLoss of modifier of cell adhesion reveals a pathway leading to axonal degeneration.Differential expression of cytoskeletal genes in the cochlear nucleus.Integrative proteomic analysis of the nucleus accumbens in rhesus monkeys following cocaine self-administrationTraumatic white matter injury and glial activation: from basic science to clinics.Vision and vision-related outcome measures in multiple sclerosis.CSF biomarkers for improved prognostic accuracy in acute CNS disease.Cerebrospinal fluid neurofilament concentration reflects disease severity in frontotemporal degeneration.Neurofilaments as a plasma biomarker for ICU-acquired weakness: an observational pilot studyUbiquitin C-terminal hydrolase-L1 as a biomarker for ischemic and traumatic brain injury in rats.Oligodendrocyte loss during the disease course in a canine model of the lysosomal storage disease fucosidosisSoluble beta-amyloid precursor protein is related to disease progression in amyotrophic lateral sclerosisBlood and CSF Biomarker Dynamics in Multiple Sclerosis: Implications for Data Interpretation.Evidence that a panel of neurodegeneration biomarkers predicts vasospasm, infarction, and outcome in aneurysmal subarachnoid hemorrhageAxonal damage in the making: neurofilament phosphorylation, proton mobility and magnetisation transfer in multiple sclerosis normal appearing white matter.Pelizaeus-Merzbacher-like disease caused by AIMP1/p43 homozygous mutation.Bone marrow mesenchymal stem cells repair spinal cord ischemia/reperfusion injury by promoting axonal growth and anti-autophagy.Purkinje Cell Pathology and Loss in Multiple Sclerosis Cerebellum.In vivo monitoring of neuronal loss in traumatic brain injury: a microdialysis study.Effects of repeated intrathecal triamcinolone-acetonide application on cerebrospinal fluid biomarkers of axonal damage and glial activity in multiple sclerosis patients.Production of IL-16 correlates with CD4+ Th1 inflammation and phosphorylation of axonal cytoskeleton in multiple sclerosis lesions.Diffuse axonal injury in brain trauma: insights from alterations in neurofilaments.The optic nerve head is the site of axonal transport disruption, axonal cytoskeleton damage and putative axonal regeneration failure in a rat model of glaucomaIncreased neurofilament light chain blood levels in neurodegenerative neurological diseases.Variation in MAPT is not a contributing factor to the incomplete penetrance in LHON.Body fluid biomarkers in multiple sclerosis: how far we have come and how they could affect the clinic now and in the futureActivated microglia mediate axoglial disruption that contributes to axonal injury in multiple sclerosisT-cell-mediated disruption of the neuronal microtubule network: correlation with early reversible axonal dysfunction in acute experimental autoimmune encephalomyelitis.Glutamate excitotoxicity is involved in the induction of paralysis in mice after infection by a human coronavirus with a single point mutation in its spike protein.Fingolimod and CSF neurofilament light chain levels in relapsing-remitting multiple sclerosisPlasma neurofilament heavy chain levels and disease progression in amyotrophic lateral sclerosis: insights from a longitudinal study.Combination of serum phosphorylated neurofilament heavy subunit and hyperintensity of intramedullary T2W on magnetic resonance imaging provides better prognostic value of canine thoracolumbar intervertebral disc herniation.Neurofilament light chain: A prognostic biomarker in amyotrophic lateral sclerosis.
P2860
Q24597181-505003B0-DD40-4A22-9F05-69BFABB1E09DQ27012726-0CE79B2E-290D-4F7E-92FB-F5E51CC0C936Q27026660-2F7B824E-67E1-404D-A823-96BDCA343338Q27301278-37B8A4C4-F659-4A64-ABCE-9702B7AD104BQ28118389-490C3CA6-847F-43E7-BB18-89E5D57EA8BDQ28481340-808F01EC-6F04-48A6-83CB-AC4921F39F5EQ28512069-8F485309-FC2E-4072-8861-D477865824ACQ30413689-ABD51159-0D44-45F9-8B6A-44AB523E56FAQ30487070-86C8564E-57E7-4B4B-99E4-0F43381A00CEQ30492995-9CA779F9-35C9-46B5-A8AC-B9AB068B2FD7Q30504753-E3874C22-B7FF-4D7D-938A-FBC5CF6D2694Q30816308-858F2170-0B95-4E13-87E4-B1EBDB2D6B44Q30872452-D9C132A7-0547-412D-8021-4127015B6572Q33313220-88B58B7C-F41B-42C2-8D51-84601AD58C6AQ33610029-F9A581F9-5769-48E8-8E8B-E7E8C0EFBCF2Q33753792-1B0837BA-35A5-4FDA-8EFA-B60141D61EA1Q33793699-5C7291DD-2E04-4B65-8874-224630357536Q33980271-C3844D6B-7F93-42D8-8565-EF5DB82F3F9EQ33999870-F378E88A-E4FF-4B22-9CFD-04D36880EB04Q34078026-9F79DE07-A344-4BF0-8189-6C513AD1AD6AQ34103510-7B37D0A5-B822-4880-9BF4-4472A2669B5AQ34220288-4528400C-489A-49E6-B036-D1A71B9B716CQ34381818-7448743B-36A0-4438-8BC4-BD70F95901FBQ34412723-F2FCDF4A-8836-49D3-A693-8D2CD215AB9CQ34448702-D2F5B941-2915-4F23-92BE-85DAA81070CCQ34538926-380CA7DD-8CB3-43DA-8FA1-81A94E5E4EA5Q34577625-592D71BC-3A3F-4ACE-BA5D-50E2C1E5C829Q34715993-F7AD8DA7-6284-40DF-8D92-F4E363D4A60DQ34722271-06114899-C8B8-4D92-886E-1CBD928168A5Q34995800-92F54EB5-E994-448D-9191-94658BB015EEQ35000781-3ABD2B73-8588-48D9-8572-7175668AF862Q35045343-DC963ECA-CA3B-4866-8B33-F192571F8423Q35078327-4D49D0A0-BC2E-47BD-8870-260CAACAFDD1Q35103843-37AF08CE-66AB-4A8C-9883-D8F18BF6E113Q35222043-0A95A8D9-522B-4DC0-935F-D53D11635A02Q35531623-82743805-B9AA-400F-A65A-DD726BAABD00Q35537489-41F0FA72-5508-4EF2-B074-83468728432DQ35550715-D3A5B9EF-ED7D-4808-9BF9-3393F48B3D1DQ35594427-A1F91CB8-0CD6-4918-9C26-48B2C1F1BF6EQ35686186-4117ED09-A98D-4B7C-9D6D-3131B1C0B1C8
P2860
Neurofilament phosphoforms: surrogate markers for axonal injury, degeneration and loss.
description
2005 nî lūn-bûn
@nan
2005年の論文
@ja
2005年論文
@yue
2005年論文
@zh-hant
2005年論文
@zh-hk
2005年論文
@zh-mo
2005年論文
@zh-tw
2005年论文
@wuu
2005年论文
@zh
2005年论文
@zh-cn
name
Neurofilament phosphoforms: surrogate markers for axonal injury, degeneration and loss.
@ast
Neurofilament phosphoforms: surrogate markers for axonal injury, degeneration and loss.
@en
type
label
Neurofilament phosphoforms: surrogate markers for axonal injury, degeneration and loss.
@ast
Neurofilament phosphoforms: surrogate markers for axonal injury, degeneration and loss.
@en
prefLabel
Neurofilament phosphoforms: surrogate markers for axonal injury, degeneration and loss.
@ast
Neurofilament phosphoforms: surrogate markers for axonal injury, degeneration and loss.
@en
P1476
Neurofilament phosphoforms: surrogate markers for axonal injury, degeneration and loss.
@en
P2093
Axel Petzold
P304
P356
10.1016/J.JNS.2005.03.015
P577
2005-06-01T00:00:00Z